'Cryo-Fluorescence Tomography, a technique to bridge multi-resolution multi-modal assays' lecture

Mohammed Fahroud, co-founder of EMIT imaging, will be visiting Ghent on Friday 19/10 and giving a talk on a novel preclinical imaging modality.

abstract:
The ability to engineer mouse models with human cancer is valuable tool used by research groups around the world to better understand the biology of disease and drug targeting characteristics.  Many human cancer cell lines have been engineered to express fluorescence so that in vivo imaging can be used to monitor and stage disease progression. Following in vivo imaging, traditional histo-pathology can be performed to validate in vivo measurements. However, a gap in sensitivity and resolution between in vivo and ex vivo techniques may make it hard to characterize an animal model.  In vivo fluorescence allows for monitoring of tumor progression over time. Traditional ex vivo techniques only focus on small sample sizes while allowing for high-resolution evaluation and characterization. Using a Cryo-Fluorescence Tomography (CFT) imaging approach, an imaging modality based on serial slicing and off-the-block fluorescence imaging, we can bridge the gap between in vivo and ex vivo resolution of the entire animal.